The biopharma sector experienced what Mike Nelson called a “selective recovery” in the first half of 2026, with notable rebounds in capital markets and an uptick in financing volume, according to a Jul. 8 report from BioSpace.
Nelson, a partner at law firm Cooley, said that while there has been an increase in initial public offerings—18 biotechs have gone public since the start of the year compared to eight during all of 2025—investment is largely focused on later-stage assets with near-term clinical catalysts. He said that later-stage rounds totaled $4.5 billion over 51 deals in the first quarter, marking “the highest Q1 value in recent years.” Early-stage financing is on pace for its lowest annual count since before the pandemic.
Ben Zercher, senior biotech and pharma analyst at PitchBook, said that although some early-stage series A and B rounds exceeded $100 million this year, many were raised by companies founded five or more years ago with relatively mature operations and clinical-stage programs. Robert Stanislaro of FTI Consulting said that large venture capital raises by established firms are pulling up overall funding numbers but noted investors are not expanding their tolerance for risk: “Investors will write early checks when the science is unusually strong, the syndicate is high-quality, or the path to a near-term catalyst is credible.”
Among major fundraises was Isomorphic Labs’ $2.1 billion series B round in May—the second largest biotech round ever—despite not yet disclosing any drug candidates. The company’s platform uses AlphaFold models to predict molecular structures and interactions; AlphaFold won a Nobel Prize in Chemistry in 2024 for its accuracy predicting protein interactions. Other top fundraisers included NewLimit ($435 million), Beeline Medicines ($426.3 million), Parabilis Medicines ($305 million), and Corxel Pharmaceuticals ($287 million). These companies are working across fields such as aging therapies, immunology, oncology, and metabolic diseases.
Sharad Chandra Vinayak of DelveInsight pointed out investor interest remains high for biologics and antibodies as well as DNA- and RNA-focused therapies but added that capital has become more discerning: “This trend reflects a bigger picture: capital hasn’t dried up, but it has become far more discerning about where it goes.”
BioSpace identified these five companies as leading recipients of venture funding so far this year.
